Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$13.05 +0.94%

+$0.15 today

Market cap
$331.67M
Beta
0.48
P/E (TTM)
9.3
EPS (TTM)
$1.22
52W Low $11.98High $20.56

Volume 0.04M

Average 0.03M

CPH.TO Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Cipher Pharmaceuticals Inc.TSX: CPH.TO

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue grows, but more slowly than its trailing trend

Q1 FY2026 revenue of $12.3M rose 2.3% year over year, behind the +28.9% change in trailing-twelve-month revenue. Sequentially, it fell 0.9% from the prior quarter. Over 3 fiscal years it compounded at +35.4% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $50.14M (-2.3%) for the fiscal year ending Dec 2026, a slowdown from the +53.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.3M-0.9% QoQ
Last fiscal yearDec 2025
$51.33M+53.9% YoY
LTMMar 2026
$50.92M+28.9% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.3%+1.6%-0.7 pp
1 year+53.9%-2.3%-56.2 pp
3-year CAGR+35.4%+3.4%-32.0 pp
5-year CAGR+4.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
51.33M USD
Year-over-year change
+53.9%
4-year CAGR
+23.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How CPH.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +28.9% is the 4th highest of 8, against a peer median of +26.1%.
  • Over three fiscal years its annual growth of +35.4% compares with a peer median of +12.4%.
CPH.TO Competitors
Revenue for CPH.TO and competitors
Company Period LTM YoY 3-year CAGR
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$510.45M CAD+36.9%+15.3%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$318.43M CAD-7.2%+11.2%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$310.92M CAD+15.6%-5.1%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$274.19M CAD+41.3%—
TSND.TOTerrAscend Corp.LTM Mar 2026$261.74M USD-8.7%+3.3%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$51.17M USD+65.5%+207.5%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$50.92M USD+28.9%+35.4%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$2.76M CAD+26.1%+13.6%
Peer median (excluding CPH.TO) —+26.1%+12.4%

Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.94M20.68M21.16M33.36M51.33M
Cost of Revenue3.68M3.99M4.07M9.26M17.56M
Gross Profit18.26M16.68M17.09M24.1M33.77M
Gross Margin83.2%80.7%80.8%72.2%65.8%
Research & Development88K98K139K021.37K
Selling, General & Admin5.11M4.4M5.43M12.24M16.3M
Operating Expenses6.45M5.63M5.56M16.26M16.97M
Depreciation & Amortization701K989K1.23M4.02M7.23M
EBITDA13.66M12.04M11.53M11.87M24.1M
EBITDA Margin62.2%58.2%54.5%35.6%46.9%
Operating Income11.82M12.04M11.53M7.85M16.8M
Operating Margin53.9%58.2%54.5%23.5%32.7%
Interest Income12K464K1.87M330K0
Interest Expense92K0001.19M
Other Income / Expenses(2M)(560K)1.15M(4.89M)661.38K
Income Before Tax11.06M11.48M12.68M2.96M17.46M
Pre-Tax Margin50.4%55.5%59.9%8.9%34.0%
Income Tax Expense3.3M(15.16M)(7.7M)(8.59M)(10.34M)
Net Income7.76M26.64M20.38M11.55M27.81M
Net Margin35.4%128.8%96.3%34.6%54.2%
EPS (Basic)0.291.060.800.471.09
EPS (Diluted)0.291.040.800.471.07
Weighted Avg Shares26.6M25.13M25.48M24.72M25.48M
Weighted Avg Shares (Diluted)26.83M25.59M25.42M24.57M25.99M

Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Intrinsic Alpha fair value

Locked

Current Price

$13.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.